vorinostat has been researched along with Chemical and Drug Induced Liver Injury in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 9.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 5.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Chen, M | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Tong, W | 1 |
| Gordon, SW | 1 |
| McGuire, WP | 1 |
| Shafer, DA | 1 |
| Sterling, RK | 1 |
| Lee, HM | 1 |
| Matherly, SC | 1 |
| Roberts, JD | 1 |
| Bose, P | 1 |
| Tombes, MB | 1 |
| Shrader, EE | 1 |
| Ryan, AA | 1 |
| Kmieciak, M | 1 |
| Nguyen, T | 1 |
| Deng, X | 1 |
| Bandyopadhyay, D | 1 |
| Dent, P | 1 |
| Poklepovic, AS | 1 |
| Zhao, Y | 1 |
| Zhou, P | 1 |
| Liu, B | 1 |
| Bambakidis, T | 1 |
| Mazitschek, R | 1 |
| Alam, HB | 1 |
| Li, Y | 1 |
| Lin, K | 1 |
| Zhang, Q | 1 |
| Liu, Z | 1 |
| Yang, S | 1 |
| Lin, Y | 1 |
| Wen, C | 1 |
| Zheng, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma[NCT01075113] | Phase 1 | 16 participants (Actual) | Interventional | 2010-08-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for vorinostat and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
1 trial available for vorinostat and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug I | 2019 |
4 other studies available for vorinostat and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Protective effect of suberoylanilide hydroxamic acid against lipopolysaccharide-induced liver damage in rodents.
Topics: Animals; Caspase 3; Caspase 9; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Disease Mod | 2015 |
Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.
Topics: Administration, Oral; Animals; Bupropion; Chemical and Drug Induced Liver Injury; Chromatography, Li | 2015 |